BCL2 and cancer: Similarly, ropivacaine has been found to activate the caspase 3 signaling pathway in hepatocellular carcinoma [33], and ropivacaine can activate the cleaved PARP and decrease Bcl-2 protein to induce apoptosis in other cancer cells [56,57].